Promising New Antifungal Treatment Targeting Chorismate Synthase from .

Authors:
Cidnei Marschalk
Cidnei Marschalk
Departamento de Bioquímica
Marina Toplak
Marina Toplak
Institute of Biochemistry
Frankfurt am Main | Germany
Peter Macheroux
Peter Macheroux
Graz University of Technology
Austria
Erika Seki Kioshima
Erika Seki Kioshima
Universidade Estadual de Maringá

Antimicrob Agents Chemother 2019 Jan 21;63(1). Epub 2018 Dec 21.

Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá, Paraná, Brazil

Paracoccidioidomycosis (PCM), caused by , is a systemic mycosis with granulomatous character and a restricted therapeutic arsenal. The aim of this work was to search for new alternatives to treat largely neglected tropical mycosis, such as PCM. In this context, the enzymes of the shikimate pathway constitute excellent drug targets for conferring selective toxicity because this pathway is absent in humans but essential for the fungus. In this work, we have used a homology model of the chorismate synthase (EC 4.2.3.5) from (CS) and performed a combination of virtual screening and molecular dynamics testing to identify new potential inhibitors. The best hit, CP1, successfully adhered to pharmacological criteria (adsorption, distribution, metabolism, excretion, and toxicity) and was therefore used in experiments. Here we demonstrate that CP1 binds with a dissociation constant of 64 ± 1 μM to recombinant chorismate synthase from and inhibits enzymatic activity, with a 50% inhibitory concentration (IC) of 47 ± 5 μM. As expected, CP1 showed no toxicity in three cell lines. On the other hand, CP1 reduced the fungal burden in lungs from treated mice, similar to itraconazole. In addition, histopathological analysis showed that animals treated with CP1 displayed less lung tissue infiltration, fewer yeast cells, and large areas with preserved architecture. Therefore, CP1 was able to control PCM in mice with a lower inflammatory response and is thus a promising candidate and lead structure for the development of drugs useful in PCM treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.01097-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325199PMC
January 2019
16 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter: Cidmarschalk
October 28, 2018, 12:33 pm EST
twitter
Twitter: GermHunterMD
October 23, 2018, 10:03 am EST

Publication Analysis

Top Keywords

chorismate synthase
12
cp1
6
displayed lung
4
best hit
4
inhibitors best
4
potential inhibitors
4
testing identify
4
identify potential
4
lung tissue
4
hit cp1
4
tissue infiltration
4
treated cp1
4
criteria adsorption
4
adsorption distribution
4
pharmacological criteria
4
adhered pharmacological
4
cp1 adhered
4
cp1 displayed
4
animals treated
4
dynamics testing
4

References

(Supplied by CrossRef)
Epidemiology, clinical, and therapeutic aspects of paracoccidioidomycosis
da Costa et al.
Trop Mycol Curr Trop Med Rep 2014
Paracocidioidomycosis mortality in Brazil (1980–1995)
Coutinho et al.
Cad Saude Publica 2002
New trends in paracoccidioidomycosis epidemiology
Martinez et al.
J Fungi (Basel) 2017
Neglected endemic mycoses
Queiroz-Telles et al.
Lancet Infect Dis 2017
Comparative genomics allowed the identification of drug targets against human fungal pathogens
Abadio et al.
BMC Genomics 2011
The shikimate pathway—a metabolic tree with many branches
Bentley et al.
Crit Rev Biochem Mol Biol 1990
Glyphosate: a once-in-a-century herbicide
Duke et al.
Pest Manag Sci 2008

Similar Publications